The only other supplier of cash is stockholders. By tripling its share count a drug developer can raise the cash to do its own phase 3 trials. That makes every share worth 1/3 of what it was worth before. It usually is better for the existing shareholders to make a deal with big pharma. BTW, if NNVC succeeds it will become one of those big pharma companies itself. Are you going to still hate on big pharma then?
News 
Market Data 
Discover 
AI
